• Pexidartinib (PLX3397) for CSF1R-Mediated Tumor Macrophage M

  2026-05-29

  Pexidartinib (PLX3397) empowers cancer researchers to precisely modulate tumor-associated macrophages via selective CSF1R inhibition. This article explores optimized workflows, new experimental paradigms, and troubleshooting strategies for leveraging Pexidartinib in translational oncology, with practical guidance drawn from the latest reference breakthroughs.

• QPRT Drives Breast Cancer Invasion via P2Y11-Mediated Signal

  2026-05-29

  Liu et al. (2021) identify quinolinate phosphoribosyltransferase (QPRT) as a promoter of breast cancer cell invasiveness through phosphorylation of myosin light chain, implicating purinergic P2Y11 receptor signaling. These findings highlight QPRT and P2Y11 antagonism as mechanistically relevant targets for understanding and potentially modulating breast cancer progression.

• Pazopanib (GW-786034): Advancing Translational Oncology Insi

  2026-05-28

  This thought-leadership article explores the mechanistic rationale and translational promise of Pazopanib (GW-786034) as a multi-targeted RTK inhibitor in cancer research, with a special focus on ATRX-deficient glioma models. Synthesizing latest peer-reviewed evidence and strategic recommendations, it provides actionable guidance for translational researchers seeking to harness the full experimental and clinical potential of angiogenesis inhibition.

• Hematoxylin and Eosin Staining Kit: Protocol and QC Guidance

  2026-05-28

  The Hematoxylin and Eosin Staining Kit (SKU: K1142) provides standardized, ready-to-use solutions for efficient cellular and tissue morphology visualization in research settings. It streamlines histopathological and cytological staining workflows for paraffin and frozen sections, but is not suitable for diagnostic or clinical use.

• MG-132 (Z-LLL-al): Unraveling Proteasome Inhibition for Auto

  2026-05-27

  Explore the multifaceted scientific impact of MG-132 as a proteasome inhibitor in autophagy, oxidative stress, and cancer research. This article provides advanced mechanistic insight and practical guidance for experimental design, setting it apart from standard MG-132 overviews.

• ROS-Responsive Nanoplatform Repairs M1 Macrophages in Diabet

  2026-05-27

  This study introduces a hierarchically targeted, ROS-responsive hydrogel platform for treating diabetic periodontitis by selectively repairing mitochondrial dysfunction in M1 macrophages. The findings demonstrate significant reduction of inflammation and tissue damage, offering a mechanistically novel approach beyond conventional bacterial debridement.

• IWP-2 in Cancer and Immunology: Beyond Wnt Inhibition

  2026-05-26

  Explore the advanced applications of IWP-2 as a potent Wnt production inhibitor, uniquely positioned at the intersection of cancer research and immunological modulation. This article delivers deep mechanistic insight and practical protocol guidance for innovative scientists.

• Pazopanib Hydrochloride: Optimized Workflows for Cancer Rese

  2026-05-26

  Pazopanib Hydrochloride (GW786034) empowers advanced anti-angiogenic and cytotoxic assays, enabling reproducible modeling of tumor suppression across diverse cancer types. This article delivers actionable protocol enhancements, troubleshooting strategies, and research insights that maximize the translational impact of this multi-target kinase inhibitor.

• Palbociclib (PD0332991): Advancing Tumor Microenvironment Re

  2026-05-25

  This thought-leadership article explores the mechanistic and translational impact of Palbociclib (PD0332991) Isethionate in next-generation cancer models. By integrating recent advances in assembloid technology and cell cycle biology, we provide strategic guidance for translational researchers seeking to optimize experimental design, interpret drug response variability, and bridge bench findings to clinical strategies. The discussion is grounded in recent reference studies and highlights APExBIO’s product reliability in complex model systems.

• Nirmatrelvir (PF-07321332): Applied Workflows for SARS-CoV-2

  2026-05-25

  Nirmatrelvir (PF-07321332) enables targeted SARS-CoV-2 3CL protease inhibition in advanced antiviral therapeutics research. This article details actionable experimental workflows and troubleshooting strategies, translating cutting-edge findings into practical, optimized bench applications.

• Doxycycline in Mechanotransduction: Beyond Antimicrobial Act

  2026-05-24

  Explore Doxycycline, a tetracycline antibiotic, as a precision tool in mechanotransduction and stem cell niche studies. Discover unique insights into its role as a metalloproteinase inhibitor and its advanced applications in cancer and matrix biology research.

• Dehydroepiandrosterone in PCOS & Neuroprotection Workflows

  2026-05-23

  Dehydroepiandrosterone (DHEA) unlocks advanced experimental models for both ovarian and neural research, bridging the gap between apoptosis inhibition and granulosa cell regulation. Discover how APExBIO's DHEA enables reproducible assays, detailed troubleshooting, and translational insights for PCOS and neuroprotection studies.

• Syringin Enhances Sunitinib Efficacy in RCC via EGFR/PI3K/Ak

  2026-05-22

  This study establishes Syringin as a bioactive natural product that inhibits renal cell carcinoma (RCC) cell proliferation, migration, and viability, while promoting apoptosis. By targeting the EGFR/PI3K/Akt pathway, Syringin also enhances RCC cell sensitivity to sunitinib, offering a promising strategy to overcome drug resistance.

• Dual Luciferase Reporter Gene System: Precision in Biolumine

  2026-05-22

  Unlock reproducible, high-throughput gene expression regulation studies using the Dual Luciferase Reporter Gene System. This guide delivers actionable workflows, troubleshooting strategies, and real-world insights, bridging advanced research findings with practical laboratory excellence.

• PDI Inhibition Enhances Panobinostat Efficacy in Multiple My

  2026-05-21

  This study demonstrates that the PDI inhibitor LTI6426 significantly enhances the anti-myeloma efficacy of panobinostat at lower, less toxic doses in preclinical models. The work identifies key ER stress pathway biomarkers and suggests new combination strategies for overcoming proteasome inhibitor resistance in multiple myeloma.

14514 records 1/968 page Next 12345 下5页 Last page